Drugs / CS3005
last change Feb 2021 re-read 3 minutes ago

CS3005

Developed for
neoplasm
Investigated by
CStone Pharmaceuticals

Trials 1

2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04233060 Jan 2020 → Jan 2021 neoplasm CStone Pharmaceuticals Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CS3005 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04233060 ↗
Route Oral “orally administrated” NCT04233060 ↗